Clinical Trial: NCT02315612
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Institutes of Health Clinical Center (CC) |
| Last Update Posted: | 2026-04-28 |
Study Overview
Brief Summary
Background:
- One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells.
Objective:
- To see if giving anti-CD22 Chimeric Antigen Receptor (CAR) cells to young people with certain cancers is safe and effective.
Eligibility:
- People ages 1-39 with a leukemia or lymphoma that has not been cured by standard therapy.
Design:
- Participants will be screened to ensure their cancer cells express the CD22 protein. They will also have medical history, physical exam, blood and urine tests, heart tests, scans, and x-rays. They may give spinal fluid or have bone marrow tests.
- Participants may have eye and neurologic exams.
- Participants will get a central venous catheter or a catheter in a large vein.
- Participants will have white blood cells removed. Blood is removed through a needle in an arm. White blood cells are removed. The rest of the blood is returned by needle in the other arm.
- The cells will be changed in a laboratory.
- Participants will get two IV chemotherapy drugs over 4 days. Some will stay in the hospital for this.
- All participants will be in the hospital to get anti-CD22 CAR cells through IV. They will stay until any bad side effects are gone.
- Participants will have many blood tests. They may repeat some screening exams.
- Participants will have monthly visits for 2-3 months, then every 3-6 months. They may repeat some screening exams.
- Participants will have follow-up for 15 years.
Official Title
Conditions
Intervention / Treatment
- Biological: CD22-CAR
Other Study ID Numbers
- 150029
- 15-C-0029
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Institutes of Health Clinical Center (CC) |
| Last Update Posted: | 2026-04-28 |
Study Overview
Brief Summary
Background:
- One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells.
Objective:
- To see if giving anti-CD22 Chimeric Antigen Receptor (CAR) cells to young people with certain cancers is safe and effective.
Eligibility:
- People ages 1-39 with a leukemia or lymphoma that has not been cured by standard therapy.
Design:
- Participants will be screened to ensure their cancer cells express the CD22 protein. They will also have medical history, physical exam, blood and urine tests, heart tests, scans, and x-rays. They may give spinal fluid or have bone marrow tests.
- Participants may have eye and neurologic exams.
- Participants will get a central venous catheter or a catheter in a large vein.
- Participants will have white blood cells removed. Blood is removed through a needle in an arm. White blood cells are removed. The rest of the blood is returned by needle in the other arm.
- The cells will be changed in a laboratory.
- Participants will get two IV chemotherapy drugs over 4 days. Some will stay in the hospital for this.
- All participants will be in the hospital to get anti-CD22 CAR cells through IV. They will stay until any bad side effects are gone.
- Participants will have many blood tests. They may repeat some screening exams.
- Participants will have monthly visits for 2-3 months, then every 3-6 months. They may repeat some screening exams.
- Participants will have follow-up for 15 years.
Official Title
Conditions
Intervention / Treatment
- Biological: CD22-CAR
Other Study ID Numbers
- 150029
- 15-C-0029